Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

20 Oct 2017
Change (% chg)

$0.22 (+4.43%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ECYT.OQ


Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin... (more)


Sell Hold Buy
2.00 Mean rating from 2 analysts


Beta: 1.77
Market Cap(Mil.): $244.81
Shares Outstanding(Mil.): 42.58
Dividend: --
Yield (%): --

BRIEF-Peter Dodwell reports 7.1 pct passive stake in Endocyte Inc

* Peter Dodwell reports 7.1 percent passive stake in Endocyte Inc ‍​as of September 29 - SEC filing Source text : (http://bit.ly/2gyKxWH) Further company coverage:

US STOCKS-Futures higher as focus shifts to earnings

Oct 3 U.S. stock index futures were slightly higher on Tuesday, a day after all the three main indexes hit new all-time highs, with investors turning their attention to the upcoming third-quarter corporate earnings.

BRIEF-Endocyte announces worldwide license of its radioligand therapy

* Endocyte announces exclusive worldwide license of phase 3 ready PSMA-targeted radioligand therapy for development in prostate cancer

BRIEF-Endocyte says ABX GmbH eligible for milestones of up to $160 mln under license agreement

* Endocyte Inc - ‍ABX is eligible for regulatory and commercial milestones of up to $160 million, and tiered royalties beginning in mid-teens​

BRIEF-Endocyte Q2 loss per share $0.28

* Endocyte reports second quarter financial results and provides clinical and pipeline update

BRIEF-Endocyte form 4 discloses CEO's 44,285 stock options fully vested on May 31, immediately exercisable

* Endocyte Inc form 4 discloses that CEO Michael Sherman's 44,285 stock options (right to buy) fully vested on may 31 and immediately exercisable - sec filing Source text (http://bit.ly/2rytsCJ) Further company coverage:

BRIEF-Endocyte announces clinical updates for EC1456 and EC1169

* Endocyte Inc - continuing EC1169 program in taxane-exposed patients, but ending clinical development of EC1456 and of EC1169 in taxane-naïve patients

BRIEF-Endocyte Q1 loss per share $0.27

* Endocyte reports first quarter financial results and provides clinical and pipeline update


  • U.S.
  • Europa
  • Asien
  • Branchen


Energie +0.25%
Rohstoffe +0.25%
Industrie -0.07%
Konjunktur abhängige Waren & Dienstleistungen -0.32%
Konjunktur unabhängige Waren & Dienstleistungen +0.39%
Finanzindustrie -0.04%
Pharma +0.50%
Technologie -0.21%
Telekommunikation -0.14%

Nachrichten aus der Wirtschaft


Jamaika-Sondierer wollen "schwarze Null" verteidigen

Berlin Trotz milliardenschwerer Wünsche der beteiligten Parteien an einer möglichen Jamaika-Koalition soll die "schwarze Null" im Bundeshaushalt erhalten bleiben.